Thermo Fisher Scientific (TMO) Receivables (2009 - 2026)

Thermo Fisher Scientific has reported Receivables for 18 years, with the latest figure at $11.1 billion in Q2 2026.

• Receivables for Q2 2026 came in at $11.1 billion, up 11.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.1 billion (up 11.0% YoY), and the FY2025 annual result was $10.6 billion, up 9.77% from the prior year.
• Receivables rose to $11.1 billion in Q2 2026, from $10.9 billion in the prior quarter.
• Over five years, Receivables peaked at $11.1 billion in Q2 2026 and troughed at $8.9 billion in Q3 2022.
• A 5-year average of $9.8 billion and a median of $9.6 billion in 2023 frame the typical range for Receivables.
• The widest annual swing landed in 2022, when Receivables jumped 41.59%; it then retreated 0.59% in 2024.
• A 5-year view of Receivables shows it stood at $9.4 billion in 2022, then climbed by 2.51% to $9.7 billion in 2023, then dropped by 0.39% to $9.6 billion in 2024, then advanced by 9.77% to $10.6 billion in 2025, then increased by 5.42% to $11.1 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $11.1 billion in Q2 2026, $10.9 billion in Q1 2026, and $10.6 billion in Q4 2025.